Safety and Effectiveness of Autologous Regenerative Cell Therapy on Pain and Inflammation Associated With Osteoarthritis of the Hip
This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the hip. Follow-up will consist of a larger sample including 4,000 patients.
• Patients with indication of Osteoarthritis. Can be from degeneration or chronic injury.
• Patients range from 18-90 years of age.
• Patients must be able to comply with treatment plan, laboratory tests and periodic interviews.
• Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl.
• Patients with adequate cardiac and respiratory function.
• Patients with adequate blood coagulation activity, PT(INR) \< 1.5, APTT
• Patients must have adequate immune system function, with no known immunodeficiency disease.
• Greater than 6 months hip pain with the index side (left or right).